Hoerter Steven L. 4/A

What Happened

• Steven L. Hoerter, a director of MBX Biosciences, was the recipient of an equity award (transaction code A) dated 2025-11-22 that is reported on this Form 4 as 0 shares at $0.00 (a derivative award). This is a grant/compensation event — not a purchase or sale — and no cash proceeds were reported.

Key Details

• Transaction date: 2025-11-22. This Form 4 is an amended filing dated 2026-04-22.
• Reported transaction: Award/Grant (A) of 0 shares at $0.00 (derivative security).
• Vesting: The grant will vest in equal monthly installments over one year beginning November 6, 2025, subject to continued service (Footnote F2).
• Compensation cap: Grants were adjusted so the non-employee director’s annual equity compensation for 2025 does not exceed $1,000,000 based on grant-date fair value under ASC 718 (Footnote F1).
• Shares owned after transaction: Not stated in the provided data.
• Filing status: This is an amended Form 4; the amendment was filed on 2026-04-22 for the 2025-11-22 transaction.

Context

• This was a compensation award to a non-employee director (not a market buy or sale). Derivative awards to directors commonly represent restricted stock units or similar equity compensation that vest over time; they do not produce immediate cash or indicate a buy/sell decision by the insider.